The license agreement was executed under the direction of UCL Business Ltd (UCLB), part of UCL Innovation & Enterprise. Based on the research of Professor Thomas Voit at the UCL GOSH Institute of Child Health, the agreement covers UCL’s leading expertise in gene therapy.“Early stage partnerships are critical to expedite innovation in gene therapy research and development. UCL is one of the world’s leading research centers and is ideally suited to help us expand our pipeline of gene therapies for cardiomyopathies,” said Dr. Valeria Ricotti, chief medical officer at DiNAQOR.
- Forums
- ASX - By Stock
- PER
- Where others have failed will Atl1102 succeed ?
Where others have failed will Atl1102 succeed ?, page-904
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.5¢ |
Change
0.001(1.19%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.5¢ | 8.5¢ | 8.5¢ | $515 | 6.056K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 262571 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 254287 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 268761 | 0.084 |
1 | 10000 | 0.083 |
2 | 193598 | 0.082 |
3 | 529037 | 0.081 |
5 | 18608 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 254287 | 3 |
0.088 | 13868 | 1 |
0.089 | 14285 | 1 |
0.090 | 546175 | 2 |
0.091 | 108000 | 1 |
Last trade - 10.24am 20/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online